Trial Profile

A Phase III prospective study of ACP-204 for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP).

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 29 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACP 204 (Primary)
Indications Delusions; Hallucinations; Psychotic disorders
Focus Therapeutic Use
Sponsors Acadia Pharmaceuticals

Most Recent Events

28 Nov 2023 According to Acadia Pharmaceuticals media release, the company announced that the clinical trial sites will enroll seamlessly from Phase 2 into Phase 3.
28 Nov 2023 According to Acadia Pharmaceuticals media release, the company plans Phase 3 Clinical Trial of ACP-204 for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP).
28 Nov 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com